What is Atlas Genetics?
Atlas Genetics is a company focused on transforming healthcare through point-of-care molecular diagnostics. Their core mission is to enhance convenient and equitable access to healthcare services. The company's flagship product, binx io, is a molecular testing platform designed for the rapid diagnosis and treatment of infections such as chlamydia and gonorrhea, enabling same-visit care. By partnering with various healthcare providers, Atlas Genetics aims to dismantle traditional barriers to care and significantly improve patient experiences. Their target clientele includes healthcare facilities and organizations seeking to bolster their diagnostic capabilities and advance their sexual health services.
How much funding has Atlas Genetics raised?
Atlas Genetics has raised a total of $85.9M across 4 funding rounds:
Series A
$2.5M
Series B
$28.4M
Series C
$20M
Series D
$35M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2014): $28.4M led by YFM Equity Partners, BB Biotech Ventures, Novartis, Life Sciences Partners, Johnson & Johnson Development Corporation, and Consort Medical - UK
Series C (2015): $20M supported by BB Biotech Ventures, RMI Partners, Novartis, Johnson & Johnson, RusnanoMedInvest, Life Sciences Partners, and Consort Medical - UK
Series D (2017): $35M featuring Wondfo Biotech, Consort Medical - UK, BB Biotech Ventures, Johnson & Johnson, Technology Venture Partners, RMI Partners, and Novartis Venture Fund
Key Investors in Atlas Genetics
Wondfo Biotech
Wondfo Biotech is a leading entity in the point-of-care testing (POCT) sector, specializing in in vitro diagnostics (IVD). They offer a wide array of reagents and advanced diagnostic devices for various medical needs, including infectious diseases and diabetes, serving clients in over 150 countries.
BB Biotech Ventures
BB Biotech Ventures is a venture capital firm dedicated to the healthcare sector, investing in private companies developing drugs, medical devices, and healthcare services. They leverage extensive experience in healthcare investments to maximize investor returns.
Johnson & Johnson
Johnson & Johnson is a global healthcare conglomerate that develops pharmaceuticals and medical technologies, including innovative medicines and surgical products, serving healthcare providers and patients worldwide.
What's next for Atlas Genetics?
The recent major strategic investment indicates Atlas Genetics is poised for significant scaling and market expansion. This capital infusion is likely to accelerate product development, enhance manufacturing capabilities, and broaden the company's commercial reach. With a focus on point-of-care diagnostics, Atlas Genetics is strategically positioned to capitalize on the growing demand for rapid, accessible testing solutions, potentially leading to further strategic partnerships and market penetration in the global healthcare landscape.
See full Atlas Genetics company page
